Fortress Biotech, Inc. (FBIO): R&D Expense
$11.90M
Year ended 2025-12-31
$1.19M
Trailing 12 months to 2026-06-30
-55.4%
3-year compound annual growth
-27.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.90M | -79.0% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $56.63M | -44.3% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $101.75M | -24.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $134.20M | +18.5% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $113.24M | +84.8% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $61.27M | +906.2% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $6.09M | -92.7% | 2021-04-09, From 2019-01-01 |
| 2018-12-31 | $83.33M | n/a | 2020-03-16, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $115.11M | +16.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
| Journey Medical Corp (DERM) | 2025-12-31 | $480.0K | -95.1% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $0 | -100.0% |
Compare FBIO, NUVB, TNGX, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗